Search clinical trials for: Somatuline (Lanreotide Autogel®)

Total 65 results

Ipsen

Completed

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour (NET729)

Non Functioning Entero-pancreatic Endocrine Tumour

United Kingdom, France, Spain, United States, Belgium, Czechia, Italy, Slovakia, Poland
Ipsen

Completed

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (IMIO)

Intestinal Obstruction

Belgium
Radboud University Medical Center

Unknown

Treatment of the Dumping Syndrome With Lanreotide Autogel®

Dumping Syndrome

Netherlands
Sheba Medical Center

Completed

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

Congenital Hyperinsulinism

Israel
Ipsen

Terminated

Predictive Factors Study (TAPAS)

Acromegaly

Australia
Ipsen

Completed

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome (ELECT)

Carcinoid Syndrome

United States, Turkey, Brazil, India, Ukraine, South Africa, Czechia, Latvia, Poland, Russian Federation, Serbia
Ipsen

Completed

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel (SALSA)

Acromegaly

United States
Ipsen

Completed

Somatuline Predictive Factors in Acromegaly and NET (SOPRANo)

Acromegaly | Neuroendocrine Tumours

Switzerland, Austria, Germany
Universitaire Ziekenhuizen KU Leuven
Ipsen

Completed

SOMATULINE Autogel 90 mg IN DUMPING SYNDROME

Dumping Syndrome

Belgium
University Medical Center Groningen
Radboud University Medical Center; Erasmus Medical Center; Leiden University...

Unknown

Study of Lanreotide to Treat Polycystic Kidney Disease (DIPAK1)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Netherlands
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours

Spain
Federico II University
Ospedali dei Colli

Completed

GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma (SS-HCC)

Advanced Hepatocellular Carcinoma

Italy
Asan Medical Center
Samsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaborators

Recruiting

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs (AIM-NETs)

Neuroendocrine Tumors

Korea, Republic of
Ipsen

Completed

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs (PALACE)

Gastroenteropancreatic Neuroendocrine Tumor

China
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Acromegaly

France, Switzerland
University Hospital, Ghent
Ipsen

Completed

Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma

Rectal Carcinoma

Belgium
Ipsen

Completed

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Acromegaly

United Kingdom
Ipsen

Completed

Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea (MEDARD)

Diarrhea

Belgium
Saint John's Cancer Institute

Terminated

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

Acromegaly

United States
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
Ipsen

Completed

Somatuline Autogel Preference and Health Economy Study (SAPHE)

Neuroendocrine Tumour With Carcinoid Symptoms

Denmark, Norway, Sweden
Ipsen

Terminated

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (QoL in IMBO)

Intestinal Obstruction

Italy
Ipsen

Withdrawn

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Acromegaly

Mexico
Ipsen

Completed

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects (LEAD)

Acromegaly

France, Brazil, Denmark, Finland, Greece, Korea, Republic of, Latvia, Netherlands, Norway, Poland, Romania, Russian Federation, Serbia, Sweden
Ipsen

Completed

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (PRIMARYS)

Acromegaly

Netherlands, Germany, France, United Kingdom, Turkey, Belgium, Czechia, Finland, Italy
Ipsen

Completed

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

Acromegaly

United States, Germany, Hong Kong, Czechia, France, Hungary, Netherlands, United Kingdom
Ipsen

Completed

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Acromegaly

Germany, Netherlands, Sweden, Czechia, Denmark, France, Greece, Italy, Spain, United Kingdom
SCRI Development Innovations, LLC
Ipsen

Terminated

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Gastrointestinal Neoplasms | Neuroendocrine Tumors | Carcinoid Tumors

United States
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Recruiting

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors,Gastroenteropancreatic

Taiwan
Ipsen

Completed

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours (CLARINET)

Endocrine Tumors

United States, United Kingdom, Netherlands, Belgium, Sweden, Spain, France, Denmark, India, Germany, Austria, Czechia, Italy, Poland, Slovakia
Ipsen

Completed

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Acromegaly

Australia
Federico II University
University of Genova

Completed

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly (ATG1line)

Acromegaly

Italy
Radboud University Medical Center
Ipsen

Completed

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE) (RESOLVE)

Polycystic Liver Disease

Netherlands
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly (LANTERN)

Acromegaly

China
Northwell Health
Ipsen

Completed

Lanreotide in the Treatment of Small Bowel Motility Disorders

Intestinal Disease | Gastrointestinal Motility Disorder

United States
University Hospital, Grenoble

Completed

Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues (PHRC-Merkel)

Carcinoma, Merkel Cell

France
Universitair Ziekenhuis Brussel

Unknown

Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy

Acid Reflux Esophagitis | Non-acid Reflux Esophagitis

Belgium
Universitaire Ziekenhuizen KU Leuven
Ipsen

Completed

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease (LOCKCYST)

Polycystic Liver Disease

Belgium
Antonio Fojo
Ipsen

Recruiting

LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (LAMPARA)

Pheochromocytoma | Paraganglioma

United States
Ipsen

Completed

Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly

Acromegaly

Italy
University of Washington

Completed

A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

Pancreatectomy; Hyperglycemia | Pancreatic Fistula | Pancreaticoduodenal; Fistula | Pancreatic Leak

United States
Ipsen

Terminated

Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

Thyroid-Associated Ophthalmopathy

Spain
Odense University Hospital

Completed

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

Acromegaly

Denmark
European Organisation for Research and Treatment...
Ipsen

Withdrawn

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome (TELEFIRST)

Small Intestinal NET | Carcinoid Heart Disease
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. (ATLANT)

Neuroendocrine Tumours

Italy
Ipsen

Terminated

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours (SPINET)

Neuroendocrine Tumors in Lung

Canada, United States, Germany, France, United Kingdom, Netherlands, Spain, Denmark, Italy, Austria, Poland
Ipsen

Completed

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

Acromegaly

Germany
Ipsen

Completed

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (SONNET)

Gastroenteropancreatic Neuroendocrine Tumors

Germany, Austria
Cedars-Sinai Medical Center

Terminated

Acromegaly Combination Treatment Study

Acromegaly

United States

3

Subscribe